Skip to main content

Table 2 Characteristics of subjects in each cohort

From: Randomized, double-blind, placebo-controlled phase I dose escalation study of Dan Qi Tong Mai tablet in healthy volunteers

Parameter

Study

Cohort

Group receiving active ingredients

Group receiving placebo

Z*

P*

Age (year)

Single-dose

1

29.00 (9.59)

24.00 (7.07)

−0.23

0.83

2

21.83 (1.47)

22.00 (0.00)

0.17

0.87

3

23.83 (1.17)

22.00 (1.41)

−0.69

0.51

4

24.00 (2.53)

24.50 (3.54)

0.00

1.00

5

23.83 (2.04)

23.00 (1.41)

−0.34

0.75

6

23.83 (0.98)

23.00 (1.41)

0.00

1.00

7

25.67 (1.97)

25.00 (0.00)

−0.17

0.87

8

24.75 (0.96)

24.00 (1.41)

−0.48

0.65

Multiple-dose

9

24.00 (2.28)

24.00 (1.41)

0.17

0.87

10

23.83 (2.40)

23.50 (3.54)

0.00

1.00

11

22.50 (1.64)

22.50 (0.71)

1.70

0.13

Height (cm)

Single-dose

1

167.00 (8.08)

168.50 (12.02)

0.00

1.00

2

165.17 (9.85)

162.50 (10.61)

−0.34

0.74

3

169.17 (7.08)

169.00 (15.56)

0.00

1.00

4

167.67 (6.98)

166.00 (8.45)

0.00

1.00

5

168.17 (4.71)

166.00 (8.49)

−0.17

0.87

6

165.17 (12.06)

164.50 (7.78)

0.17

0.87

7

166.33 (6.95)

167.00 (14.14)

0.00

1.00

8

166.50 (6.95)

160.00 (0.00)

−0.70

0.48

Multiple-dose

9

163.00 (9.12)

164.00 (5.66)

0.34

0.74

10

169.50 (7.45)

172.50 (0.71)

0.50

0.62

11

167.00 (7.32)

159.00 (12.73)

−0.67

0.50

Weight (kg)

Single-dose

1

57.75 (9.22)

62.00 (14.14)

0.46

0.64

2

56.33 (10.54)

58.00 (4.24)

0.50

0.62

3

58.83 (10.63)

64.00 (12.73)

0.67

0.50

4

60.83 (8.80)

58.50 (9.19)

−0.17

0.86

5

59.83 (4.31)

54.50 (7.78)

−1.07

0.29

6

58.17 (9.06)

56.50 (10.61)

−0.51

0.61

7

59.00 (7.32)

56.50 (13.44)

−0.17

0.87

8

59.50 (6.66)

49.50 (0.71)

−1.41

0.16

Multiple-dose

9

58.17 (12.95)

57.50 (3.54)

0.00

1.00

10

62.33 (9.35)

62.50 (3.54)

0.17

0.87

11

60.42 (8.18)

54.75 (13.79)

−0.50

0.62

Body mass index (kg/m2)

Single-dose

1

20.59 (1.23)

21.60 (1.83)

1.16

0.25

2

20.53 (1.63)

22.00 (1.26)

0.83

0.40

3

20.41 (2.03)

22.28 (0.35)

1.17

0.24

4

21.54 (1.73)

21.14 (1.17)

−0.17

0.87

5

21.14 (1.00)

19.72 (0.82)

−1.50

0.13

6

21.25 (1.47)

20.77 (1.96)

−0.50

0.62

7

21.30 (2.08)

20.07 (1.41)

−0.83

0.40

8

21.40 (0.95)

19.34 (0.28)

−1.62

0.11

Multiple-dose

9

21.24 (1.67)

21.37 (0.16)

0.00

1.00

10

21.58 (1.52)

21.01 (1.36)

−0.84

0.40

11

21.57 (1.39)

21.43 (2.02)

0.00

1.00

  1. Values are mean (SD)
  2. *Wilcoxon test